Clinical Trials

43 enrolled

Colorectal Neoplasms

NCT04221438 2026-05-12

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT05195632 2026-05-01

OCEANII

63 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05004350 2026-04-30

NAUTICALCRC

107 enrolled 69 charts

Colorectal Neoplasms

NCT05308446 2026-04-21

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

84 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

35 enrolled

Melanoma

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT05217446 2026-04-07

SEAMARK

107 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04324112 2026-03-31

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Other hematologic neoplasm

45 enrolled

Leukemia, Hairy Cell

NCT04074096 2026-03-25

BEPCOME-MB

10 enrolled

Brain Neoplasms, Melanoma

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05926960 2026-03-09

PORTSIDE

38 enrolled

Melanoma, Skin Neoplasms

NCT06578559 2026-01-05

BRICKET

16 enrolled

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

Brain Neoplasms, Melanoma

NCT04526782 2025-11-18

ENCO-BRAF

119 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05510895 2025-10-01

NeoBRAF

2 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06887088 2025-10-01

ENCEFALO

33 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Melanoma

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

112 enrolled

Brain Neoplasms, Melanoma

NCT05706779 2025-09-02

NEORAF

30 enrolled

Colorectal Neoplasms

NCT03235245 2025-08-01

EBIN

271 enrolled

Melanoma

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Melanoma, Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

48 enrolled 24 charts

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT06640166 2025-02-12

ECLYPse

25 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT03839342 2025-02-03

BEAVER

26 enrolled

Other solid neoplasm

Solid Tumor

NCT05097599 2025-01-08

StrataPATH

11 enrolled

Tumor-Agnostic

Neoplasms

NCT06411600 2024-11-08

BRAVE

94 enrolled

Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

5 enrolled 15 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

251 enrolled

Melanoma

NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

6 enrolled 16 charts

Pancreatic Neoplasms

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Melanoma

NCT03693170 2024-02-02

ANCHOR-CRC

95 enrolled 30 charts

Colorectal Neoplasms

NCT02834364 2023-11-24

GMMG-BIRMA

12 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03563729 2023-07-13

MEMBRAINS

80 enrolled

Brain Neoplasms, Melanoma

NCT03911869 2023-05-31

POLARIS

13 enrolled 55 charts

Brain Neoplasms, Melanoma

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Phase 2 Unknown

28 enrolled

Melanoma

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Colorectal Neoplasms

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

45 enrolled

Melanoma, Neoplasms

NCT01719380 2021-06-23

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

156 enrolled 41 charts

Colorectal Neoplasms

NCT01981187 2021-03-26

SIGNATURE

Other hematologic neoplasm

12 enrolled 13 charts

Hematologic Neoplasms

NCT02109653 2020-11-13

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn

Melanoma

NCT01820364 2017-01-09

LOGIC

15 enrolled 13 charts